Wockhardt Zaynich wins CDSCO nod for adult cUTI 2026

What Wockhardt announced

Wockhardt Ltd said it has received approval from India’s Central Drugs Standard Control Organisation (CDSCO) for the import and marketing of its antibiotic Zaynich (Zidebactam/Cefepime) in India. The company disclosed the update in a regulatory filing. The approval covers adult patients aged 18 years and above. The immediate focus is complicated urinary tract infections (cUTI), a serious category that often requires hospital-based care. Wockhardt also said the approved label includes cUTI cases with concurrent Gram-negative bacteremia. The development is notable because the company has positioned Zaynich as an indigenously discovered and developed antibiotic.

Indication cleared by the regulator

According to Wockhardt, CDSCO’s approval is for adults with complicated urinary tract infections, including pyelonephritis. Pyelonephritis refers to kidney infection, which can become severe when linked to resistant bacteria. The company also highlighted concurrent Gram-negative bacteremia as part of the approved treatment scope. This is important because bacteremia implies bacteria in the bloodstream, which increases clinical risk. The statement places Zaynich within a set of hospital-relevant infections where timely antibiotic choice matters. The filing did not provide pricing or launch timelines.

Evidence cited: the ENHANCE-1 Phase 3 trial

Wockhardt said the CDSCO nod is supported by results from the pivotal ENHANCE-1 study. The company described ENHANCE-1 as a multinational, randomised, double-blind Phase 3 clinical trial. The study evaluated the efficacy and safety of Zaynich compared with meropenem in patients with cUTI, including pyelonephritis. In another company update included in the provided material, Wockhardt said the Phase 3 trial was conducted across 64 sites in the US, Europe, Latin America, China and India. It also said the trial enrolled 530 patients for complicated UTI and acute pyelonephritis (cUTI/AP). Wockhardt stated that Zaynich showed superiority over meropenem on a combined clinical and microbiological cure endpoint.

Additional clinical package referenced by the company

Beyond ENHANCE-1, the company’s broader dataset described in the material includes nine Phase 1 studies and a multi-indication Phase 2 study. Wockhardt also referred to evaluation in meropenem-resistant infections and gram-negative infections in this Phase 2 work. Separately, it said data from 85 compassionate-use cases was part of the dossier reviewed by the CDSCO Subject Expert Committee (SEC) in the context of marketing permission. The compassionate-use cases were reported across India, the US, Malaysia and France, in situations where no safe and efficacious alternatives were available. These elements indicate the company has built evidence across controlled trials and harder-to-treat real-world settings, as described in its communications.

How Zaynich is designed to work

Zaynich combines two agents, Cefepime and Zidebactam. Wockhardt said the combination disrupts bacterial cell wall formation and binds a key protein, PBP2, which is essential for bacterial survival. The company has positioned this approach as relevant for difficult gram-negative infections, including drug-resistant cases. The filings and summaries provided do not include detailed resistance pattern data by geography, but they repeatedly reference meropenem-resistant and extensively drug-resistant (XDR) gram-negative pathogens.

Standards support cited: CLSI breakpoint

Wockhardt also cited recognition from the Clinical and Laboratory Standards Institute (CLSI). It said CLSI has assigned Cefepime/Zidebactam an investigational susceptible breakpoint of 64 mg/L. The company linked this breakpoint to Zaynich’s potential broad-spectrum coverage, particularly against clinically important XDR gram-negative pathogens in critically ill patients. The statement is framed as supportive context rather than a separate regulatory approval. Still, it signals the company’s intent to place the drug in high-acuity care settings where drug resistance is a key constraint.

Earlier regulatory step: Subject Expert Committee recommendation

In separate updates included in the provided text, Wockhardt said Zaynich received a favourable recommendation for marketing permission from the CDSCO Subject Expert Committee (SEC). The company described this SEC opinion as a step toward final approval by the Drugs Controller General of India (DCGI), and noted that such recommendations are typically a precursor though not binding. One of the included reports said the SEC recommendation was announced on March 30, 2026. Another item in the material states that Wockhardt has now received CDSCO approval for import and marketing, indicating regulatory progress beyond the expert panel stage. The company communications cited the same broad dataset for the SEC review, including non-clinical data, nine Phase 1 studies, Phase 2 and Phase 3 data, and compassionate-use cases.

Key figures and facts at a glance

Market impact: what investors typically track here

For investors, the immediate takeaway is that Wockhardt has communicated a regulatory clearance for import and marketing in India for Zaynich, along with a clear adult cUTI label scope. The company has anchored the approval on a pivotal Phase 3 program versus meropenem, a key comparator in hospital antibiotic practice. It has also highlighted clinical settings that often involve intensive care and drug resistance, such as concurrent bacteremia and XDR gram-negative infections. The provided material does not include projected sales, pricing, capacity plans, or launch dates, so financial impact cannot be quantified from the available text. Still, the existence of an approved indication and the size of the Phase 3 program are likely to be central reference points for market participants following Wockhardt’s anti-infective pipeline.

Global regulatory progress mentioned

Wockhardt also said the US health regulator has accepted the New Drug Application (NDA) for Zaynich. The company stated the NDA was filed on September 30, 2025, and that the acceptance marks a major milestone. The provided text does not include a decision date, review timeline, or label details for the US. It also mentions that approval is awaited in India, the US, and the EU in the context of launch, but separately states CDSCO approval for India. Readers should therefore treat each update based on what it explicitly says: India marketing approval is reported in one item, while other items describe the pathway and pending decisions in multiple jurisdictions.

Conclusion

Wockhardt has reported receiving CDSCO approval to import and market Zaynich in India for adult complicated urinary tract infections, including pyelonephritis, and cUTI with concurrent Gram-negative bacteremia. The company has tied the clearance to Phase 3 ENHANCE-1 results versus meropenem, and to a broader clinical package spanning Phase 1, Phase 2 and compassionate-use data. In parallel, Wockhardt has also said the US health regulator accepted its NDA filed in September 2025. The next concrete updates investors are likely to watch for are commercial rollout details for India and further regulatory milestones outside India, where the company has indicated applications are in motion.